Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024
Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (Nasdaq: LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market.
加利福尼亞州南舊金山，2024年4月25日（GLOBE NEWSWIRE）——標準生物工具公司（“標準生物工具” 或 “公司”）（納斯達克股票代碼：LAB）今天宣佈，將在2024年5月8日星期三收盤後公佈2024年第一季度財務業績。
The Company's management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on May 8, 2024, to discuss first quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call.
公司管理層將於太平洋時間2024年5月8日下午 1:30，美國東部時間下午 4:30 主持電話會議和網絡直播，討論2024年第一季度的財務業績和運營進展。包括財務業績的新聞稿將在電話會議之前公開發布。
Individuals interested in listening to the conference call may do so by dialing:
有興趣收聽電話會議的個人可以通過撥打以下電話進行收聽：
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
美國國內來電者：(888) 346-3970
美國以外的來電者：(412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company's website at Events & Presentations. The webcast will be archived and available on Standard BioTools Investor Relations page at investors.standardbio.com.
網絡直播的直播音頻將在公司網站的 “投資者關係” 頁面的 “活動與演講” 上在線提供。網絡直播將存檔並在Standard BioTools投資者關係頁面上播放 投資者.standardbio.com。
About Standard BioTools Inc.
關於標準生物工具公司
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook, LinkedIn, and YouTube.
標準生物工具公司（納斯達克股票代碼：Lab）是SomaLogic Inc.的母公司，前身爲Fluidigm Corporation，其驅動力是一個大膽的目標——釋放工具，加速人類健康領域的突破。Standard BioTools擁有成熟的下一代基本標準化技術組合，可幫助生物醫學研究人員更快、更好地開發藥物。作爲領先的解決方案提供商，該公司使用其專有的質量細胞術和微流控技術提供有關健康和疾病的可靠和可重複的見解，這有助於將科學發現轉化爲更好的患者預後。Standard BioTools與全球領先的學術、政府、製藥、生物技術、動植物研究和臨床實驗室合作，專注於轉化和臨床研究中最緊迫的需求，包括腫瘤學、免疫學和免疫療法。在 standardbio.com 上了解更多信息或通過 X、Facebook 聯繫我們、領英和YouTube。
For Research Use Only. Not for use in diagnostic procedures.
僅供研究使用。不用於診斷程序。
Limited Use Label License and other terms may apply: . Patent and License Information: . Trademarks: . Any other trademarks are the sole property of their respective owners. 2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
有限使用標籤許可和其他條款可能適用:.專利和許可信息:.商標：。任何其他商標均爲其各自所有者的專有財產。2024 Standard BioTools Inc.（又名 Fluidigm Corporation）。版權所有。
Investor Contact:
投資者聯繫人：
David Holmes
Gilmartin Group LLC
ir@standardbio.com
大衛霍姆斯
吉爾馬丁集團有限責任公司
ir@standardbio.com
譯文內容由第三人軟體翻譯。